lutetium has been researched along with African Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arndt, MA; Bötticher, B; Grosse-Hovest, L; Haberkorn, U; Jäger, D; Keller, A; Krämer, S; Krauss, J; Leotta, K; Mier, W; Sauter, M; Schlegelmilch, A; Weber, T | 1 |
| Arndt, MA; Bötticher, B; Brem, G; Exner, E; Gröne, HJ; Grosse-Hovest, L; Haberkorn, U; Jäger, D; Keller, A; Krämer, S; Krauss, J; Leotta, K; Mier, W; Sauter, M; Strumberg, D; Weber, T; Wischnjow, A | 1 |
2 other study(ies) available for lutetium and African Lymphoma
| Article | Year |
|---|---|
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Topics: Animals; Burkitt Lymphoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Immunoglobulin G; Lutetium; Maximum Tolerated Dose; Mice; Mice, Inbred NOD; Radioimmunotherapy; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Xenograft Model Antitumor Assays | 2016 |
Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Burkitt Lymphoma; Cell Line, Tumor; Female; Forkhead Transcription Factors; Homeodomain Proteins; Humans; Immunoconjugates; Immunoglobulins, Intravenous; Interleukin Receptor Common gamma Subunit; Lutetium; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Radioimmunotherapy; Radioisotopes; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |